BioMed Research International / 2014 / Article / Tab 2

Review Article

Multiparametric MRI for Recurrent Prostate Cancer Post Radical Prostatectomy and Postradiation Therapy

Table 2

Characteristics of the different reviewed studies on mp-MRI for the diagnosis of local recurrence after RT.

AuthorsMRI scanStudy designCasesMean PSAReference standardT2WIDCEMRSIDWICombined techniques

Sala et al. [12]PAC + ERC 1.5-T Prospective453.57 ng/dLWhole-mount RP sectionSe 36–76%
Spe 65–81%
0.61–0.75

Westphalen et al. [13]PAC + ERC 1.5-T Retrospective59TRUS biopsySe 62–74%
Sp 64–68%
PPV 70–80%
NPV 50–70%
Acc 63–71%

Rouvière et al. [14]PAC 1.5-T Prospective226.36 ng/dLTRUS biopsySe 26–44%
Sp 64–86%
PPV 47–63%
NPV 61–69%
Acc 54–60%
Se 70–74%
Sp 73–85%
PPV 68–78%
NPV 78-79%
Acc 73–79%

Haider et al. [15]PAC 1.5-T Prospective332.1 ng/dLTRUS biopsySe 38%
Sp 80%
PPV 24%
NPV 88%
Acc 74%
Se 72%
Sp 85%
PPV 46%
NPV 95%
Acc 83%

Kara et al. [16]PAC 1.5-T Retrospective20TRUS biopsySe 86.7%
Sp 100%
PPV 100%
NPV 71%
Acc 90%
Se 93.3%
Sp 100%
PPV 100%
NPV 83.3%
Acc 95%

Menard et al. [17]Prospective35TRUS biopsySe 88.9%
Sp 92%
PPV 91.7%
Acc 91.4%

Coakley et al. [18]PAC + ERC 1.5-T Retrospective212.3 ng/dLTRUS biopsy 0.49–0.51Se 89%
Sp 82%
PPV 64%
NPV 96%
0.81

Pucar et al. [19]PAC + ERC 1.5-T Prospective93.7 ng/dLWhole-mount RP sectionSe 68%
Sp 96%
Se 77%
Sp 78%

Westphalen et al. [20]PAC + ERC 1.5-T Retrospective642.6 ng/dLTRUS biopsy 0.67T2WI + MRS:
0.79

Wu et al. [9]MetanalysisSe 74%
Spe 65%
Se 90%
Spe 81%
MRSI + DCE:
Se 90%
Spe 90%

Tamada et al. [21]PAC 1.5-T Retrospective167.42 ng/dLTRUS biopsySe 27%
Sp 99%
PPV 86%
NPV 87%
Acc 87%
Se 50%
Sp 98%
PPV 85%
NPV 90%
Acc 90%
Se 68%
Sp 95%
PPV 75%
NPV 94%
Acc 91%
T2WI + DCE + DWI:
Se 77%
Sp 92%
PPV 68%
NPV 95%
Acc 90%

Kim et al. [22]PAC 3.0-T Prospective363.44 ng/dLTRUS biopsySe 25%
Sp 92%
PPV 57%
NPV 74%
0.612
T2WI + DWI:
Se 62%
Sp 97%
PPV 91%
NPV 81%
0.879

Morgan et al. [23]ERC 1.5-TRetrospective24TRUS biopsySe 93.8%
Sp 75%
PPV 8.2%
NPV 85.7%

Hara et al. [24]PAC 1.5-T Retrospective104.44 ng/dLTRUS biopsySe 69%
Sp 91%
PPV 37%
NPV 97%
Acc 89%

Arumainayagam et al. [25]PAC 1.5-TRetrospective13TRUS biopsyT2WI + DCE + DWI:
0.86–0.93

Westphalen et al. [26]PAC + ERC 3.0-T Retrospective262.5 ng/dLTRUS biopsy 0.616
0.830
0.755
T2WI + MRS + DWI:
0.869
MRS + DWI:
0.863
T2WI + MRS:
0.841
T2WI + DWI:
0.774

Kim et al. [27]PAC 3.0-T Retrospective242.76 ng/dLTRUS biopsySe 27%
Sp 80%
PPV 32%
NPV 76%
Acc 67%
0.594
Se 49%
Sp 92%
PPV 67%
NPV 84%
Acc 81%
0.737
Se 49%
Sp 93%
PPV 72%
NPV 84%
Acc 82%
0.782
DCE + DWI:
Se 59%
Sp 91%
PPV 69%
NPV 87%
Acc 83%
0.863

Akin et al. [28]PAC + ERC 1.5-TRetrospective241.63 ng/dLTRUS biopsySe 13–81%
Sp 25–88%
0.53–0.64
T2WI + DCE + DWI:
Se 81–94%
Sp 75–100%
0.86–0.95

Donati et al. [29]PAC + ERC 1.5 or 3.0-TRetrospective53TRUS biopsySe 54–66%
Sp 39–61%
PPV 63–77%
NPV 30–48%
0.46–0.632
T2WI + DCE:
Se 60–63%
Sp 56–89%
PPV 73–91%
NPV 44–53%
0.601–0.830
T2WI + DWI:
Se 54–83%
Sp 89–94%
PPV 93–95%
NPV 52–73%
0.812–0.863
T2WI + DCE + DWI:
Se 49–71%
Sp 94%
PPV 94–96%
NPV 49–63%
0.722–0.879

Roy et al. [11]PAC + ERC 3.0-T Retrospective323.6 ng/dLTRUS biopsySe 74% Se 94%Se 74%Se 94% T2WI + DCE: Se 91%
T2WI + DWI + DCE:
Se 100%
T2WI + DWI + DCE + MRS:
Se 76%
T2WI + DWI: Se 94%
T2WI + MRS: 44%

PAC: phased-array coil; ERC: endorectal coil; Se: sensitivity; Spe: specificity; PPV: positive predictive value; NPV: negative predictive value; Acc: accuracy; : area under the receiver operating curve.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.